well known for their involvement in allergic and anaphylactic reactions 20 ; then, surface bound immunoglobulin E (IgE) complexes with specific antigen, causing degranulation, like a foil package of popcorn popping until the contents overflow. 21 Many of these molecules are preformed and stored in almost 500 secretory granules, while others are made do novo during or following stimulation. 22, 23 It is fascinating that one cell should have such plethora and diversity of potent molecules that include arachidonic acid products, biogenic amines, chemoattractants, cytokines, growth factors, neuropeptides, proteoglycans, and proteolytic enzymes ( Table 2) . Although the mast cell is ubiquitous in the body-including the brain, which does not suffer from allergic reactions because IgE does not cross the blood-brain barrier-degranulation occurs only in about 10% or so of atopic individuals. Moreover, increasing evidence indicates that some molecules are released from mast cells without degranulation, a process termed "differential release" and first reported for serotonin. 24 Other biogenic amines 25 , arachidonic acid products 26 , and cytokines 27 may also be released differentially. The morphological appearance of this process is characterized by a more subtle set of changes within the electron dense content of the secretory granules 28 and has been called "piece-meal degranulation" 29 or "intergranular activation". 30 The type(s) of molecule(s) released may vary from person to person, and/or from organ to organ, depending on hormonal and psychological state and the specific trigger.
Anatomical and functional associations have been reported between mast cells and neurons. 31, 32 Scanning electron microscopy has documented mast cells close to endothelial cells and to neuronal processes. 33 Molecules released from nerves [34] [35] [36] , such substance P (SP), neurotensin (NT), nerve growth factor (NGF), and opioids 37 could trigger mast cells (Table 3) , from which histamine could stimulate neuronal depolarization 38 , which could lead to further activation of mast cells. Moreover, mast cell derived chondroitin sulfate or heparin complexes with NGF and extends its half-life from a few minutes to many hours. 39, 40 Therefore, mast cell activation could lead to abnormal nerve proliferation (i.e., in neurofibromatosis I). 41 Intracranial mast cells could also be activated by stimulation of the trigeminal 42 , sympathetic 43 , or sphenopalatine 44 nerves and by acute restraint stress 45 , in the absence of any allergic diathesis. Some molecules from these mast cells could have direct effects on the brain, while others could make the bloodbrain barrier "leaky" and permit circulating chemicals to enter the brain. 46, 47 Breakdown of the blood-brain barrier has been shown to precede any clinical or radi- Vasodilation, neurotransmission CSF, colony stimulating factor; INF␥, interferon-␥; MIF, macrophage inflammatory factor; b-FGF, fibroblast growth factor; NGF, nerve growth factor; TGF-␤, transforming growth factor-␤; TNF-␣, tumor necrosis factor-␣; SRIF, somatostatin; GM-CSF, granulcyte monocyte-colony stimulating factor. ographic signs of MS. 48 Therefore, it is of interest that chemical 49 or stress-induced stimulation of brain mast cells 50 increased blood-brain barrier permeability. Moreover, experimental allergic encephalomyelitis could not be induced in mast cell deficient mice. 51 These findings support the possible relationship between intracranial mast cells and migraines 52 , as well as MS 53 , that are often precipitated or worsened by stress. [54] [55] [56] [57] Dura mast cells also express estrogen receptors 33 , a finding that, along with the report that estrogen augments mast cell secretion 58 , may possibly explain the higher incidence of migraines in women or their frequent occurrence during ovulation.
Many patients also experience tachycardia and arrhythmias related to stress. Such cardiovascular symptoms may be associated with increased sympathetic activity or reflex tachycardia in response to histamineinduced hypotension. However, such symptoms may also be explained by the recent finding that acute stress triggers mast cell activation in the heart 59 , with subsequent release of histamine 60 and IL-6. 61 This action of histamine is not blocked by the usual antihistamines and appears to be mediated through the type 3 histamine receptor. 62 IL-6, a key inflammatory cytokine 63 , is known be released from the hearts of patients with acute coronary syndrome, and is now considered a critical player in coronary artery disease. 64 Stress-induced cardiac mast cell activation may be involved in unstable angina and myocardial infarction triggered by acute stress. [65] [66] [67] Acute stress also results in bladder 68 and intestinal 69, 70 mast cell activation, which may explain why symptoms in interstitial cystitis (IC) and irritable bowel syndrome (IBS) patients worsen under stress.
Corticotropin-releasing hormone or factor (CRH or CRF) is the first molecule released under stress and activates the hypothalamic-pituitary-adrenal (PHA) axis. 71 We have shown that CRH 72 and structurally related urocortin 73 are powerful triggers of mast cell activation in the skin. In fact, urocortin was 10 times more potent than CRH and much more potent than SP. 73 These actions were mimicked by acute stress 74 and may be responsible for stress-induced alopecia areata. 75 Such findings and the presence of both CRH and CRH receptors in the skin 76 have led to the hypothesis that the skin has the equivalent of a local "pituitary-adrenal axis". 77 Recent findings showed that hypothalamic mast cell activation by chemical 78 or immunologic means 79 triggered activation of the HPA axis. This action could be mediated either through activation of CRH neurons directly or the release of IL-6, a CRH independent activator of the HPA axis. 80 CRH or urocortin then could be further released from recruited immune cells. 81 Recognizing the involvement of mast cells and regulating their secretion may be more important than simply addressing the effects of individual mediators. A case in point is the clinical report (Pehlivanidis and associates, page 221 in this issue) of a young boy mistakenly diagnosed and unsuccessfully treated for epilepsy. When it was recognized that his seizures were induced by acute stress and were associated with his mastocytosis, he was successfully treated with a combination of the anxiolytic antihistamine hydroxyzine and the tricyclic doxepin. The efficacy of these compounds may be explained by the fact that mast cell activation can be inhibited by certain tricyclic anxiolytic medications, such as amitriptyline and hydroxyzine 82 , and benzodiazepines. 83 In fact, mast cells have been reported to express high affinity benzodiazepine receptors. 84, 85 Hydroxyzine was recently shown to inhibit neurogenic inflammation and experimental allergic encephalomyelitis in rats. 86 In humans, hydroxyzine has been used successfully to treat acute pain 87 and remitting-relapsing MS. 88 Such anxiolytic molecules could be combined with naturally occurring flavonoids 89 or proteoglycans 90 for more efficient inhibition of mast cell Measles; parainfluenza; Sendai activation. Behavioral modification for stress reduction also contributed to the treatment of the child described in the case report by Pehlivanidis and associates. We used this approach because of our finding that training in relaxation led to a sharp decline in the frequency and severity of migraines and the release of the mast cell marker tryptase 11 in children. The mast cell has been considered an immune gate to the brain 91 , as well as a sensor of environmental and emotional stress. 92 It has also been linked to many neuropathological processes. [93] [94] [95] This versatile role of mast cells 96 compels a more appropriate name to indicate its polydimensional potential, perhaps "pleiotropocyte" (Greek ϭ multifaceted cell).
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